Type 1 fibroblast growth factor receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Type 1 Fibroblast Growth Factor Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Type 1 Fibroblast Growth Factor Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Type 1 Fibroblast Growth Factor Receptor Antagonists: Overview
Fibroblast growth factor receptors (FGFRs) play an important role in embryonic development, angiogenesis, wound healing, cell proliferation and differentiation. FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands. FGFR1 signalling downstream functions mainly via PI3K and MAPK pathways. Several ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression.
Function – The FGFR1 protein spans the cell membrane, so that one end of the protein is inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR1 protein to interact with other proteins called fibroblast growth factors (FGFs) outside the cell and to receive signals that help the cell respond to its environment. When an FGF attaches to the FGFR1 protein, the receptor triggers a cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes, such as maturing to take on specialized functions. This signaling is thought to play an important role in the development and growth of several parts of the body, including the brain, bones of the head and face (craniofacial bones), bones in the hands and feet, and the long bones in the arms and legs.
Type 1 Fibroblast Growth Factor Receptor Antagonists- Frequent tumor fibroblast growth factor receptor (FGFR) alterations are seen in many cancers, and include genetic amplifications, mutations, rearrangements and fusions. FGFR inhibitors target these receptor alterations and show promise as a drug class. FGF signaling inhibition dramatically reduces revascularization, hitting upon one of the hallmarks of cancers, angiogenesis, and reduces tumor burden in human tumors that depend on autocrine FGF signaling
Type 1 Fibroblast Growth Factor Receptor Antagonists Emerging Drugs Chapters
This segment of the Type 1 Fibroblast Growth Factor Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 1 Fibroblast Growth Factor Receptor Antagonists Emerging Drugs
Further product details are provided in the report……..
Type 1 Fibroblast Growth Factor Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Type 1 Fibroblast Growth Factor Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Type 1 Fibroblast Growth Factor Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Fibroblast Growth Factor Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Fibroblast Growth Factor Receptor Antagonists drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Type 1 Fibroblast Growth Factor Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Type 1 Fibroblast Growth Factor Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Type 1 Fibroblast Growth Factor Receptor Antagonists: Overview
Fibroblast growth factor receptors (FGFRs) play an important role in embryonic development, angiogenesis, wound healing, cell proliferation and differentiation. FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands. FGFR1 signalling downstream functions mainly via PI3K and MAPK pathways. Several ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression.
Function – The FGFR1 protein spans the cell membrane, so that one end of the protein is inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR1 protein to interact with other proteins called fibroblast growth factors (FGFs) outside the cell and to receive signals that help the cell respond to its environment. When an FGF attaches to the FGFR1 protein, the receptor triggers a cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes, such as maturing to take on specialized functions. This signaling is thought to play an important role in the development and growth of several parts of the body, including the brain, bones of the head and face (craniofacial bones), bones in the hands and feet, and the long bones in the arms and legs.
Type 1 Fibroblast Growth Factor Receptor Antagonists- Frequent tumor fibroblast growth factor receptor (FGFR) alterations are seen in many cancers, and include genetic amplifications, mutations, rearrangements and fusions. FGFR inhibitors target these receptor alterations and show promise as a drug class. FGF signaling inhibition dramatically reduces revascularization, hitting upon one of the hallmarks of cancers, angiogenesis, and reduces tumor burden in human tumors that depend on autocrine FGF signaling
Type 1 Fibroblast Growth Factor Receptor Antagonists Emerging Drugs Chapters
This segment of the Type 1 Fibroblast Growth Factor Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 1 Fibroblast Growth Factor Receptor Antagonists Emerging Drugs
- ABSK 091: Abbisko Therapeutics
- Lucatinib: Clovis Oncology
Further product details are provided in the report……..
Type 1 Fibroblast Growth Factor Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Type 1 Fibroblast Growth Factor Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Type 1 Fibroblast Growth Factor Receptor Antagonists
- Phases
- Late-stage products (Phase III )
- Mid-stage products (Phase II )
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intravenous
- Intramuscular
- Oral
- Parenteral
- Subcutaneous
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Type 1 Fibroblast Growth Factor Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Fibroblast Growth Factor Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Fibroblast Growth Factor Receptor Antagonists drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Type 1 Fibroblast Growth Factor Receptor Antagonists R&D.
- The therapies under development are focused on novel approaches for Type 1 Fibroblast Growth Factor Receptor Antagonists.
- Type 1 Fibroblast Growth Factor Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Type 1 Fibroblast Growth Factor Receptor Antagonists drugs?
- How many Type 1 Fibroblast Growth Factor Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Type 1 Fibroblast Growth Factor Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 1 Fibroblast Growth Factor Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Type 1 Fibroblast Growth Factor Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Type 1 Fibroblast Growth Factor Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Type 1 Fibroblast Growth Factor Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Type 1 Fibroblast Growth Factor Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Type 1 Fibroblast Growth Factor Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ABSK 091: Abbisko Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BFKB 8488A: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Companies
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Products
Type 1 Fibroblast Growth Factor Receptor Antagonists- Unmet Needs
Type 1 Fibroblast Growth Factor Receptor Antagonists- Market Drivers and Barriers
Type 1 Fibroblast Growth Factor Receptor Antagonists- Future Perspectives and Conclusion
Type 1 Fibroblast Growth Factor Receptor Antagonists Analyst Views
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Companies
Appendix
Executive Summary
Type 1 Fibroblast Growth Factor Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Type 1 Fibroblast Growth Factor Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Type 1 Fibroblast Growth Factor Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Type 1 Fibroblast Growth Factor Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ABSK 091: Abbisko Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BFKB 8488A: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Companies
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Products
Type 1 Fibroblast Growth Factor Receptor Antagonists- Unmet Needs
Type 1 Fibroblast Growth Factor Receptor Antagonists- Market Drivers and Barriers
Type 1 Fibroblast Growth Factor Receptor Antagonists- Future Perspectives and Conclusion
Type 1 Fibroblast Growth Factor Receptor Antagonists Analyst Views
Type 1 Fibroblast Growth Factor Receptor Antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Type 1 Fibroblast Growth Factor Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Type 1 Fibroblast Growth Factor Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Type 1 Fibroblast Growth Factor Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Type 1 Fibroblast Growth Factor Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
